GSK256066 phosphodiesterase(pde) inhibitor was modestly active against cisplatin-refractory

An active drug in chemotherapy for gastric cancer. Docetaxel in patients with re U is a combination treatment with FP showed a RR of 16.7% with the OS of 8.3 months, in line with an earlier report by GSK256066 phosphodiesterase(pde) inhibitor Bang et al. Done 45 in chemotherapy patients have ı ¨. The additive effect of cisplatin can be considered insignificant. W Chentliche irinotecan monotherapy was modestly active against cisplatin-refractory Another patient with gastric cancer who had a good first ECOG-PS. S is a single agent as second-line drug was administered for refractory patients with gastric cancer, paclitaxel, and cisplatin and the results showed, and Net Assets Assets safe. S 1 was also acceptable in patients with poor PS AGC. However, S 1 could be suitable for second-line therapy in patients who do not have again 5-FU based chemotherapy U first line.
Among the drug combinations evaluated in studies with therapies based on oxaliplatin and capecitabine / doxorubicin, had more GDC-0980 1032754-93-0 than the H Half of the patients a PS 2 and the graphs showed modest efficiencies. In addition, k Nnte FOLFIRI or mitomycin and S 1 active and tolerable Be adjusted therapies. Currently, target agents, trastuzumab in combination with chemotherapy as first-line chemotherapy for HER2-positive AGC has been approved, but no target agent have approved as second-line therapy. Bang and colleagues reported that sunitinib monotherapy is insufficient clinical value as second-line treatment. An essential RESTRICTIONS LIMITATION this study is that the included studies for most phase II trials in which the prime Re endpoint was not OS, but TTP, PFS, or RR.
In addition, contain most of the studies, a small number of patients. Another RESTRICTIONS LIMITATION, is that most studies do not clearly mention the position of the tumor in the inclusion criteria. In the Korean study, the results of adenocarcinoma of the gastroesophageal Sophagealen transition of which adenocarcinoma of the stomach are separated, there is an increasing trend of adenocarcinoma of the GEJ in the L With Western countries such as Eastern. However, we note that this study is the first systematic overview of the second-line chemotherapy for gastric cancer in Korea, where FP has been accepted as standard treatment, and extensive testing of second-line therapy in MCO were. In summary, the R Established by the second-line chemotherapy in AGC has not by hard evidence, thanks to big s, randomized Phase III.
However, much indirect evidence of many phase II studies strongly suggest the extension of the PFS and RR improved through the use of second-line chemotherapy. Combination therapy is preferred as second-line treatment for gastric cancer, and platinum is still used as part of combination therapy. American Society of Clinical Oncology 2011 Annual Meeting, a great evaluate s prospective, multicenter, randomized phase III trial, whether there have been a performance of second-line chemotherapy reported there. This study compared active treatment with BSC and reported a survival advantage of second-line chemotherapy. In addition, his con k Nnten further studies Us that therapies may need during the whole treatment used Similar to treatments for cancer, for which the three drugs, 5-FU, irinotecan and oxaliplatin should investigate use

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>